» Articles » PMID: 20484589

Genetic Heterogeneity in Uveal Melanoma Assessed by Multiplex Ligation-dependent Probe Amplification

Overview
Specialty Ophthalmology
Date 2010 May 21
PMID 20484589
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine intratumor genetic heterogeneity in uveal melanoma (UM) by multiplex ligation-dependent probe amplification (MLPA) in formalin-fixed, paraffin-embedded (FFPE) tumor tissues.

Methods: DNA was extracted from whole tumor sections and from two to nine different areas microdissected from 32 FFPE UMs. Thirty-one loci on chromosomes 1, 3, 6, and 8 were tested with MLPA for copy number changes. The tumor was considered heterogeneous at a locus if (1) the difference in dosage quotients (DQs) of any two areas was 0.2 or more, and (2) the DQs of the areas belonged to different ranges.

Results: Comparison of MLPA data obtained from microdissected areas of the UMs showed heterogeneity in 1 to 26 examined loci in 24 (75%) tumors, with only 25% of the tumors being homogeneous. Intratumor heterogeneity of 3p12.2, 6p21.2, and 8q11.23 was most common, occurring in >30% of the UMs. Gains of chromosome 3 were observed in four UMs, with three of these tumors showing the highest degree of heterogeneity. Copy number variation was associated with differences in tumor cell type, but not with differences in tumor pigmentation or reactive inflammation. UMs with genetic heterogeneity across multiple sample sites showed equivocal MLPA results when the whole tumor section was examined. These results suggest that different clones dilute MLPA results.

Conclusions: Heterogeneity of chromosomal abnormalities of chromosomes 1, 3, 6, and 8 is present in most UMs. This heterogeneity causes equivocal MLPA results. One random tumor sample may not be representative of the whole tumor and, therefore, may be insufficient for prognostic testing.

Citing Articles

Microdissection of Distinct Morphological Regions Within Uveal Melanomas Identifies Novel Drug Targets.

Toumi E, Hesson L, Lin V, Wright D, Hajdu E, Lim L Cancers (Basel). 2025; 16(24.

PMID: 39766052 PMC: 11674814. DOI: 10.3390/cancers16244152.


Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.

Beigi Y, Lanjanian H, Fayazi R, Salimi M, Hoseyni B, Noroozizadeh M Mol Biomed. 2024; 5(1):17.

PMID: 38724687 PMC: 11082128. DOI: 10.1186/s43556-024-00182-2.


Quantitative Diffusion-Weighted MR Imaging: Is There a Prognostic Role in Noninvasively Predicting the Histopathologic Type of Uveal Melanomas?.

Foti P, Ini C, Broggi G, Farina R, Palmucci S, Spatola C Cancers (Basel). 2023; 15(23).

PMID: 38067331 PMC: 10705312. DOI: 10.3390/cancers15235627.


Future perspectives of uveal melanoma blood based biomarkers.

Beasley A, Chen F, Isaacs T, Gray E Br J Cancer. 2022; 126(11):1511-1528.

PMID: 35190695 PMC: 9130512. DOI: 10.1038/s41416-022-01723-8.


Small Choroidal Melanoma: Correlation between Clinical Characteristics and Metastatic Potential.

Luo S, Raval V, Zabor E, Singh A Ocul Oncol Pathol. 2022; 7(6):437-446.

PMID: 35087820 PMC: 8740206. DOI: 10.1159/000519672.